Levofloxacin

C difficile risk
High
Oral Bioavailability
Excellent
Cost
IV:$ PO:¢

Dosing

CrCl ≥30 mL/minCrCl 10-29 mL/minCrCl <10 mL/min500mg PO/IV Q24 or 750mg PO/IV Q24h500mg PO/IV, then 250mg PO/IV Q24-48hUsual initial dose, then 250-500mg PO/IV Q48h

Usual initial dose, then 250-500mg PO/IV Q48h

Load 500-750mg PO/IV, then 250-750mg PO/IV Q24h

500-750mg PO/IV daily

General Information

  • Lower respiratory infection (CAP, HAP)

  • Intraabdominal infection

Monitor QTc in patients with increased risk

  • QTc prolongation

  • Dysglycemia

  • Rash

  • Tendinopathy and rupture

  • GI upset

  • Weakness exacerbation in myasthenia gravis

  • CNS toxicity including confusion, psychosis

  • Other QTc prolonging agents

  • Divalent cations - Decreased absorption

  • NSAIDs - Increase seizure risk

  • Warfarin - Increased INR

Antimicrobial class: Fluoroquinolone

Pregnancy category: C

Average serum half life: 7 hours

Urine penetration: Therapeutic

Lung penetration: Therapeutic

Biliary penetration: Therapeutic